SS Innovations Reports Second Quarter 2025 Financial Results

Core Insights - SS Innovations International, Inc. reported record quarterly revenue of $10.0 million, a 121.8% increase from $4.5 million in Q2 2024, driven by higher sales of the SSi Mantra 3 surgical robotic system [5][4] - Gross profit more than tripled to $5.9 million, reflecting a gross margin expansion to 59.1% from 31.9% in the same quarter last year [5][4] - The company narrowed its net loss to $0.3 million, compared to a net loss of $4.1 million in Q2 2024, indicating significant operational improvements [5][4] Second Quarter 2025 Overview - Revenue increased by 121.8% to $10.0 million from $4.5 million in Q2 2024 [5] - Gross margin expanded to 59.1% from 31.9% in Q2 2024 [5] - Gross profit rose 311.4% to $5.9 million from $1.4 million in Q2 2024 [5] - Net loss decreased to $0.3 million, or $(0.00) per diluted share, from a net loss of $4.1 million, or $(0.02) per diluted share, in Q2 2024 [5] First Half 2025 Overview - Revenue for the first half of 2025 increased by 85.6% to $15.1 million from $8.1 million in the first half of 2024 [5] - Gross margin expanded to 46.3% from 26.6% in the first half of 2024 [5] - Gross profit rose 223.3% to $7.0 million from $2.2 million in the first half of 2024 [5] - Net loss for the first half of 2025 was $5.9 million, or $(0.03) per diluted share, compared to a net loss of $14.0 million, or $(0.08) per diluted share, in the first half of 2024 [5] Business Highlights - SSi Mantra surgical robotic system installations totaled 23 in Q2 2025, a 130% increase from 10 installations in Q2 2024 [5] - Cumulative installed base of SSi Mantra systems reached 105 across seven countries, with cumulative surgeries totaling 4,657 [5] - The company plans to submit a 510(k) application for multiple indications for the SSi Mantra 3 to the FDA by the end of September 2025 [4][5] CEO Commentary - The CEO emphasized the company's commitment to expanding access to robotic surgery and highlighted the successful execution of strategic initiatives leading to strong revenue growth [4] - The SSi Mantra 3 system has achieved several "world firsts" in robotic telesurgery and cardiac procedures [4] - The company is on track for European Union CE marking certification by late 2025 [4]